Biomea Fusion Inc is a biotechnology company focused on the development of targeted therapies for cancer treatment
The company leverages its proprietary drug discovery platform to identify and create innovative small molecule therapeutics aimed at addressing specific genetic mutations that drive tumor growth. By utilizing advanced technology and scientific expertise, Biomea Fusion actively works to improve patient outcomes through precision medicine, aiming to provide more effective and personalized treatment options for individuals battling various forms of cancer.
FDA has lifted the clinical hold on Biomea Fusion's BMF-219 trials for type 1 and type 2 diabetes following a safety review, allowing the ongoing studies to resume.
Biomea Fusion shares are trading lower by 62.7% during Friday's session. The company received notice from the FDA that Its trials of BMF-219 have been placed on clinical hold.
